Repotrectinib Capsules

40mg

The recommended dosage of this product is 160mg, taken orally, once a day for 14 days, then increased to 160mg, taken orally, twice a day, until disease progression or intolerable toxicity occurs (see [Pharmacokinetics]).

The safety of Ripretinib was assessed in 426 patients who received the recommended dose of Ripretinib in the Phase II study of TRIDENT-1 (initially 160 mg once daily for 14 days, then increased to 160 mg twice daily until disease progression or intolerable toxicity). Among them, 47.7% of patients were exposed for more than 6 months, and 28.2% of patients were exposed for more than 1 year or longer. The most commonly reported adverse reactions (≥20%) were dizziness (64.6%), taste distortion (56.8%), and abnormal sensations (39.2%).